Skip to contentY
Yubo International Biotech Ltd
Y
YBGJYubo International Biotech Ltd Q3 2023 · 10-Q
Revenue$428.51K$428.51K+2,839.0% vs Q3 2022 Net Income$6.29K$6.29KN/M vs Q3 2022 EPS Diluted$0.00$0.00no prior Q3 2022 on file Gross Profit$344,082+3,484.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Yubo International Biotech Ltd · CIK 895464 · Engraved from SEC EDGAR
Operating Cash Flowderived$4,976−91.0% Free Cash Flowderived$4,976−91.0% Margins · derivedGross margin80.3%+14.5 pt vs Q3 2022
Operating margin1.5%+1635.7 pt vs Q3 2022
Net margin1.5%+1634.5 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 20, 2023 · 51 d after period end